Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: EXOC6B

Gene summary for EXOC6B

Gene summary.

Gene information	Species	Human
	Gene symbol	EXOC6B
	Gene ID	23233
	Gene name	exocyst complex component 6B
	Gene Alias	SEC15B
	Cytomap	2p13.2
	Gene Type	protein-coding
	GO ID	GO:0006810
	UniProtAcc	A0A0U1RRB6

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
23233	EXOC6B	CCI_1	Human	Cervix	CC	6.80e-24	2.17e+00	0.528
23233	EXOC6B	CCI_2	Human	Cervix	CC	5.21e-15	1.44e+00	0.5249
23233	EXOC6B	CCI_3	Human	Cervix	CC	3.53e-26	1.65e+00	0.516
23233	EXOC6B	HTA11_3410_2000001011	Human	Colorectum	AD	3.42e-28	-8.58e-01	0.0155
23233	EXOC6B	HTA11_2951_2000001011	Human	Colorectum	AD	2.51e-02	-8.02e-01	0.0216
23233	EXOC6B	HTA11_411_2000001011	Human	Colorectum	SER	3.03e-03	9.58e-01	-0.2602
23233	EXOC6B	HTA11_3361_2000001011	Human	Colorectum	AD	7.26e-04	-4.85e-01	-0.1207
23233	EXOC6B	HTA11_696_2000001011	Human	Colorectum	AD	4.05e-11	-4.17e-01	-0.1464
23233	EXOC6B	HTA11_7862_2000001011	Human	Colorectum	AD	2.07e-02	-5.93e-01	-0.0179
23233	EXOC6B	HTA11_866_3004761011	Human	Colorectum	AD	1.94e-10	-6.41e-01	0.096
23233	EXOC6B	HTA11_8622_2000001021	Human	Colorectum	SER	2.27e-03	-6.21e-01	0.0528
23233	EXOC6B	HTA11_10711_2000001011	Human	Colorectum	AD	9.39e-07	-5.76e-01	0.0338
23233	EXOC6B	HTA11_7696_3000711011	Human	Colorectum	AD	2.84e-28	-6.35e-01	0.0674
23233	EXOC6B	HTA11_6818_2000001021	Human	Colorectum	AD	4.03e-05	-5.70e-01	0.0588
23233	EXOC6B	HTA11_99999970781_79442	Human	Colorectum	MSS	1.05e-27	-7.02e-01	0.294
23233	EXOC6B	HTA11_99999971662_82457	Human	Colorectum	MSS	2.62e-11	-4.41e-01	0.3859
23233	EXOC6B	HTA11_99999973899_84307	Human	Colorectum	MSS	5.78e-03	-6.69e-01	0.2585
23233	EXOC6B	HTA11_99999974143_84620	Human	Colorectum	MSS	1.62e-22	-5.44e-01	0.3005
23233	EXOC6B	A002-C-010	Human	Colorectum	FAP	4.75e-03	-2.02e-01	0.242
23233	EXOC6B	A001-C-207	Human	Colorectum	FAP	2.68e-03	-3.45e-01	0.1278

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00516567	Cervix	CC	establishment of organelle localization	76/2311	390/18723	3.17e-05	5.21e-04	76
GO:00988767	Cervix	CC	vesicle-mediated transport to the plasma membrane	34/2311	136/18723	3.75e-05	5.91e-04	34
GO:00068927	Cervix	CC	post-Golgi vesicle-mediated transport	28/2311	104/18723	4.31e-05	6.61e-04	28
GO:00481938	Cervix	CC	Golgi vesicle transport	58/2311	296/18723	2.24e-04	2.54e-03	58
GO:00068936	Cervix	CC	Golgi to plasma membrane transport	16/2311	60/18723	2.00e-03	1.46e-02	16
GO:00068873	Cervix	CC	exocytosis	59/2311	352/18723	8.74e-03	4.48e-02	59
GO:0048193	Colorectum	AD	Golgi vesicle transport	109/3918	296/18723	1.80e-10	1.68e-08	109
GO:0051656	Colorectum	AD	establishment of organelle localization	131/3918	390/18723	3.00e-09	2.06e-07	131
GO:0098876	Colorectum	AD	vesicle-mediated transport to the plasma membrane	57/3918	136/18723	2.30e-08	1.27e-06	57
GO:0006892	Colorectum	AD	post-Golgi vesicle-mediated transport	45/3918	104/18723	2.22e-07	9.26e-06	45
GO:0051650	Colorectum	AD	establishment of vesicle localization	57/3918	161/18723	1.47e-05	3.15e-04	57
GO:0006893	Colorectum	AD	Golgi to plasma membrane transport	27/3918	60/18723	2.41e-05	4.66e-04	27
GO:0051648	Colorectum	AD	vesicle localization	59/3918	177/18723	7.83e-05	1.25e-03	59
GO:0006903	Colorectum	AD	vesicle targeting	19/3918	45/18723	9.94e-04	9.28e-03	19
GO:0006887	Colorectum	AD	exocytosis	96/3918	352/18723	2.48e-03	1.90e-02	96
GO:00516561	Colorectum	SER	establishment of organelle localization	100/2897	390/18723	1.11e-07	6.79e-06	100
GO:00481931	Colorectum	SER	Golgi vesicle transport	79/2897	296/18723	4.20e-07	2.15e-05	79
GO:00068921	Colorectum	SER	post-Golgi vesicle-mediated transport	31/2897	104/18723	1.59e-04	3.08e-03	31
GO:00988761	Colorectum	SER	vesicle-mediated transport to the plasma membrane	37/2897	136/18723	3.08e-04	5.00e-03	37
GO:00516501	Colorectum	SER	establishment of vesicle localization	42/2897	161/18723	3.38e-04	5.35e-03	42

Page: 1 2 3 4 5 6 7 8 9

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

EXOC6B

SNV

Missense_Mutation

novel

c.1918N>A

p.Asp640Asn

p.D640N

protein_coding

tolerated(0.2)

possibly_damaging(0.562)

TCGA-A2-A4S1-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

EXOC6B

SNV

Missense_Mutation

c.1531T>C

p.Phe511Leu

p.F511L

protein_coding

deleterious(0.02)

probably_damaging(0.992)

TCGA-A8-A097-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

EXOC6B

SNV

Missense_Mutation

novel

c.988C>T

p.Pro330Ser

p.P330S

protein_coding

tolerated(0.34)

probably_damaging(0.999)

TCGA-BH-A0HA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

EXOC6B

SNV

Missense_Mutation

novel

c.2374N>C

p.Glu792Gln

p.E792Q

protein_coding

tolerated(0.07)

probably_damaging(0.998)

TCGA-BH-A0HQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

EXOC6B

SNV

Missense_Mutation

rs201814463

c.167N>T

p.Arg56Leu

p.R56L

protein_coding

deleterious(0.03)

probably_damaging(0.998)

TCGA-D8-A1Y1-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

tamoxiphen

EXOC6B

SNV

Missense_Mutation

c.2423N>C

p.Gly808Ala

p.G808A

protein_coding

tolerated(0.85)

benign(0.007)

TCGA-E2-A14T-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

EXOC6B

SNV

Missense_Mutation

c.880N>T

p.Pro294Ser

p.P294S

protein_coding

deleterious(0)

possibly_damaging(0.767)

TCGA-FU-A3TX-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Unknown

EXOC6B

SNV

Missense_Mutation

c.1178N>T

p.Ser393Phe

p.S393F

protein_coding

deleterious(0.01)

possibly_damaging(0.857)

TCGA-Q1-A73O-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

EXOC6B

SNV

Missense_Mutation

novel

c.1535N>T

p.Ser512Leu

p.S512L

protein_coding

tolerated(0.08)

probably_damaging(0.996)

TCGA-VS-A8EL-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

EXOC6B

SNV

Missense_Mutation

rs755302023

c.142N>T

p.Arg48Cys

p.R48C

protein_coding

deleterious(0.01)

possibly_damaging(0.761)

TCGA-A6-2684-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1